APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.

Research Highlights

The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.

Key Features

The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.

Key Issues Addressed

  • What is the current scenario of the biosimilars market in APAC, and how far will it grow?
  • What are the key factors driving the market, and what are the barriers that need to be resolved?
  • Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
  • Who are the key market participants involved, and where do they stand?
  • What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market?
  • What is the future of the biosimilars market in Asia?

Table of Contents

Executive DashboardPurpose of the Experiential Study5 Step Process to Transformational GrowthScope and SegmentationKey Questions This Study Will AnswerKey FindingsBiosimilars—Gateway to SuccessTrends in Evolving Biopharmaceuticals MarketBiosimilars Ecosystem—Industry Convergence MapEcosystem PartnershipsDisruptive Trends in the Changing Market LandscapeKey RegionsSix Big Market Themes for Global Biosimilars MarketGrowth Environment—Market Overview Market OverviewKey Challenges in the Biosimilars MarketBiosimilars Market—TimelineMarket Segmentation by Therapeutic AreasTrends in Global Biosimilars Market Global Biosimilar Patenting TrendsAreas Impacting Biosimilars AdoptionAttributes Impeding Physician Adoption of BiosimilarsDrivers and RestraintsImpact Mapping of Drivers and RestraintsBiosimilars Market ForecastsMarket Snapshot—Biosimilars MarketPercent Revenue Forecast by RegionRevenue ForecastRevenue Forecast by Molecule TypeRevenue Forecast DiscussionGrowth Pipeline, Strategy, and ImplementationMajor Growth Opportunities Growth Opportunity 1—mAb Biosimilars for CancerGrowth Opportunity 2—Insulin Glargine Biosimilars for DiabetesGrowth Opportunity 3—mAb Biosimilars for Rheumatoid ArthritisStrategic Imperatives for Success and Growth Oncology—Trastuzumab BiosimilarsTrastuzumab Biosimilars—Key ParticipantsTrastuzumab Biosimilars—Revenue ForecastTrastuzumab Biosimilars—Adoption Rate and Patient PopulationTrastuzumab Biosimilars—Price and DiscountsOncology—Bevacizumab BiosimilarsBevacizumab Biosimilar—Key ParticipantsBevacizumab Biosimilar—Revenue ForecastBevacizumab Biosimilar—Adoption Rate and Patient PopulationBevacizumab Biosimilar—Price and DiscountsDiabetes—Insulin Glargine BiosimilarsInsulin Glargine Biosimilar—Key ParticipantsInsulin Glargine Biosimilar—Revenue ForecastInsulin Glargine Biosimilar—Adoption Rate and Patient PopulationInsulin Glargine Biosimilar—Price and DiscountsRheumatoid Arthritis—Etanercept BiosimilarsEtanercept Biosimilar—Key ParticipantsEtanercept Biosimilar—Revenue ForecastEtanercept Biosimilar—Adoption Rate and Patient Population Etanercept Biosimilar—Price and DiscountsRheumatoid Arthritis—Infliximab BiosimilarsInfliximab Biosimilar—Key ParticipantsInfliximab Biosimilar—Revenue ForecastInfliximab Biosimilar—Adoption Rate and Patient Population Infliximab Biosimilar—Price and Discounts Rheumatoid Arthritis—Adalimumab BiosimilarsPipeline for Adalimumab Biosimilar—Key ParticipantsAdalimumab Biosimilar—Revenue ForecastAdalimumab Biosimilar—Adoption Rate and Patient Population Adalimumab Biosimilar—Price and DiscountsBiosimilars Market Dynamics—Why Asia?APAC—A Lucrative Market for BiosimilarsAPAC—Regulatory AuthoritiesAPAC Biosimilars—Game-changing CompaniesPatent Expiry for Blockbuster Bio-pharmaceuticalsAPAC—Future of BiosimilarsAPAC—Market AnalysisTransformation of Industry EcosystemKey Factors for New EntrantsInterchangeability Interchangeability (continued)Regional Hot SpotsCountry AttractivenessKey Companies to WatchMergers, Acquisitions, and Partnerships AssessmentMergers, Acquisitions, and Partnerships Assessment (continued)Strategies for Foreign Participants in APACFactors Influencing Uptake of Biosimilars in APACFactors Influencing Uptake of Biosimilars in APAC—DiscussionPhysicians, Patients, and Pharmacists—Perceptions and ConcernsBiosimilars Market—ChinaRevenue ForecastRevenue Forecast DiscussionMarket AnalysisSnapshot of Market Participants Regulatory EnvironmentStrategic Imperatives for China—Key TrendsBiosimilars Market—IndiaRevenue ForecastRevenue Forecast DiscussionSnapshot of Market Participants Regulatory EnvironmentStrategic Imperatives for India—Key TrendsGrowth Potential of Key Segments in Bio-tech in IndiaBiosimilars Market—South KoreaRevenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Snapshot of Market Participants Regulatory EnvironmentRegulatory Environment (continued)Strategic Imperatives for South Korea—Key TrendsBiosimilars Market—JapanRevenue ForecastRevenue Forecast DiscussionSnapshot of Market Participants Regulatory EnvironmentRegulatory Environment (continued)Strategic Imperatives for Japan—Key TrendsBiosimilars Market—AustraliaRevenue ForecastRevenue Forecast DiscussionSnapshot of Market Participants Regulatory EnvironmentStrategic Imperatives for Australia—Key TrendsConclusionVisioning Scenarios for the Biosimilars MarketVisioning Scenarios for the Biosimilars Market (continued)Visioning Scenarios for the Biosimilar Market (continued)Visioning Scenarios for the Biosimilars Market (continued)Business Model Essentials5 Competitive Keys for SuccessFuture of Biosimilars in APACLegal DisclaimerAppendixList of ExhibitsList of Exhibits (continued)List of Exhibits (continued)List of Exhibits (continued)List of Exhibits (continued)List of Exhibits (continued)Global Regulatory LandscapeGlobal Regulatory Landscape DiscussionRegulations and their Impact on the Biosimilars MarketBiosimilars—Market EvolutionBiosimilars are Not Generics—A Comparison Between Generics, Biologics, and BiosimilarsBiosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars (continued)Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars (continued)Biologics and Biosimilars—Manufacturing ProcessesDevelopment Process and Technical Requirements for BiosimilarsProduction process and technical needs are complex.Timeline for Development of a Biosimilar MedicineValue Chain Analysis—Development of a BiosimilarBig Pharma Companies (Innovators) Vs Biotech Firms Vs Generic Manufacturers


Related Research

Release Date : 02-Sep-2015

Region : Global

Release Date : 07-Oct-2014

Region : Global

Release Date : 05-May-2014

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.